Form 4 for LYEL Lyell Immunopharma, Inc.
Accepted 2025-02-26 00:00:00 ET · period of report 2025-02-10 · accession 0001415889-25-005747 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-02-26 | 2025-02-10 | LYEL | Lee Gary K. | CSO | A - Grant | $0.00 | +112.5K | 176.7K | +175% | $0 |
| DM | 2025-02-26 | 2025-02-10 | LYEL | Lee Gary K. | CSO | A - Grant | $0.00 | +506.2K | 450.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-10 | A | A | 112,500 | $0.00 | 176,696 | D | — | — | (F2) Includes 7,800 shares acquired on May 17, 2024 and 3,696 shares acquired on November 18, 2024 under the Issuer's 2021 Employee Stock Purchase Plan. |
| 2 | Derivative | Option (right to buy) | 2025-02-10 | A | A | 56,250 | $0.00 | 56,250 | D | $0.55 · — to 2035-02-09 | 56,250 Common Stock | (F4) The reported transaction involved the reporting person's receipt of a grant of performance-based options, subject to vesting upon the achievement of specified performance criteria. |
| 3 | Derivative | Option (right to buy) | 2025-02-10 | A | A | 450,000 | $0.00 | 450,000 | D | $0.55 · — to 2035-02-09 | 450,000 Common Stock | (F3) 12.5% of the option shares will vest on August 9, 2025, with the remaining option shares to vest in equal monthly installments over the following forty-two months, subject to the reporting person providing service through the applicable vesting date. |